Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: The FATSEIN study

Contemporary Clinical Trials

Volumn 32, Issue 2, 2011, Pages 244-249

  Rotonda, C ^a,b,c,d   Guillemin, F ^a,b,c   Bonnetain, F ^e   Conroy, T ^c,d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CENTRE ALEXIS VAUTRIN   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Adjuvant chemotherapy; Anthracycline; Breast cancer; EORTC QLQ C30; Fatigue; MFI 20; Quality of life; Taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; DRUG EFFECT; FEMALE; HUMAN; LONGITUDINAL STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; STATE TRAIT ANXIETY INVENTORY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FATIGUE; FEMALE; HUMANS; PROSPECTIVE STUDIES; PSYCHOLOGICAL TESTS; QUESTIONNAIRES; RESEARCH DESIGN; SAMPLE SIZE; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 79551567340     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.11.007     Document Type: Article

References (38)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
3. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Épidémiol Santé Publique 2008, 56(3):159-175.
4. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18(7):1133-1144.
5. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352(22):2302-2313.
6. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
7. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
8. Tan-Chiu E., Yothers G., Romond E., Geyer C.E., Ewer M., Keefe D., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23(31):7811-7819.
9. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998, 25(3 Suppl 7):43-46.
10. Broeckel J.A., Jacobsen P.B., Balducci L., Horton J., Lyman G.H. Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2000, 62(2):141-150.
11. Andrykowski M.A., Curran S.L., Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998, 21(1):1-18.
12. Bower J.E., Ganz P.A., Desmond K.A., Rowland J.H., Meyerowitz B.E., Belin T.R. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000, 18(4):743-753.
13. Ganz P.A., Desmond K.A., Leedham B., Rowland J.H., Meyerowitz B.E., Belin T.R. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002, 94(1):39-49.
14. Servaes P., Verhagen S., Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 2002, 13(4):589-598.
15. Piper B.F., Lindsey A.M., Dodd M.J. Fatigue mechanisms in cancer patients: developing nursing theory. Oncol Nurs Forum 1987, 14(6):17-23.
16. Richardson A. Fatigue in cancer patients: a review of the literature. Eur J Cancer Care (Engl) 1995, 4(1):20-32.
17. Vogelzang N.J., Breitbart W., Cella D., Curt G.A., Groopman J.E., Horning S.J., et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997, 34(3 Suppl 2):4-12.
18. Servaes P., Verhagen C., Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 2002, 38(1):27-43.
19. Stone P., Richards M., A'Hern R., Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000, 11(5):561-567.
20. Badger T., Segrin C., Meek P., Lopez A.M., Bonham E., Sieger A. Telephone interpersonal counseling with women with breast cancer: symptom management and quality of life. Oncol Nurs Forum 2005, 32(2):273-279.
21. Von Ah D.M., Kang D.H., Carpenter J.S. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs 2008, 31(2):134-144.
22. Berger A.M., Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 1999, 26(10):1663-1671.
23. Broeckel J.A., Jacobsen P.B., Horton J., Balducci L., Lyman G.H. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998, 16(5):1689-1696.
24. Tchen N., Juffs H.G., Downie F.P., Yi Q.L., Hu H., Chemerynsky I., et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003, 21(22):4175-4183.
25. de Jong N., Candel M.J., Schouten H.C., Abu-Saad H.H., Courtens A.M. Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 2004, 15(6):896-905.
26. de Jong N., Candel M.J., Schouten H.C., Abu-Saad H.H., Courtens A.M. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 2005, 16(3):372-382.
27. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M.., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000, 5(5):353-360.
28. Berger A.M., Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum 2000, 27(9):1443-1448.
29. Jacobsen P.B., Hann D.M., Azzarello L.M., Horton J., Balducci L., Lyman G.H. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999, 18(4):233-242.
30. Scheier M.F., Carver C.S. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol 1985, 4(3):219-247.
31. Spielberger C.D. State-Trait Anxiety Inventory: a comprehensive bibliography 1989, Consulting Psychologists Press, CA.
32. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995, 39(3):315-325.
33. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez NJ., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
34. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000, 18(20):3558-3585.
35. Gentile S., Delaroziere J.C., Favre F., Sambuc R., San Marco J.L. Validation of the French 'multidimensional fatigue inventory' (MFI 20). Eur J Cancer Care (Engl) 2003, 12(1):58-64.
36. Fayers P.A.N., Bjordal K., Curran D., Groenvold M. EORTC QLQ-C30 Scoring Manual 2001, on behalf of the EORTC Quality of Life Study Group, Brussels. Third edition.
37. Bruchon-Schweitzer M., Paulhan I. Manuel Inventaire d'anxiété Etat-Trait Forme Y (STAI-Y), vol. 1 1993, Paris. Editions du Centre de Psychologie Appliquée.
38. Mehnert A., Scherwath A., Schirmer L., Schleimer B., Petersen C., Schulz-Kindermann F., et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007, 66(1):108-118.